Hodowanec Aimee C, Han Alice, Barker David E, Rubinstein Paul G, Max Blake
1Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
J Int Assoc Physicians AIDS Care (Chic). 2012 Nov-Dec;11(6):345-7. doi: 10.1177/1545109712455460. Epub 2012 Aug 27.
Venous thrombosis is a well-described complication of thalidomide therapy in patients with multiple myeloma (MM). However, an association between thalidomide use and thrombosis in HIV-positive patients has not been previously described. We present the case of a 48-year-old HIV-positive man who developed a deep venous thrombosis while on thalidomide for the treatment of severe aphthous ulcers. We review the management of severe aphthous disease and the potential adverse effects of thalidomide therapy. We examine the association between thalidomide and thrombosis in patients with MM and discuss how the same relationship may or may not exist in HIV-positive patients. Although the strength of the association between thalidomide use and thrombosis in HIV-positive patients being treated for aphthous disease remains unclear, HIV providers should be aware of the potential risk of thrombosis in all patients receiving thalidomide.
静脉血栓形成是多发性骨髓瘤（MM）患者使用沙利度胺治疗时一种广为人知的并发症。然而，此前尚未有关于HIV阳性患者使用沙利度胺与血栓形成之间关联的描述。我们报告一例48岁HIV阳性男性病例，该患者在使用沙利度胺治疗严重阿弗他溃疡时发生了深静脉血栓形成。我们回顾了严重阿弗他病的治疗以及沙利度胺治疗的潜在不良反应。我们研究了MM患者中沙利度胺与血栓形成之间的关联，并讨论了这种关系在HIV阳性患者中可能存在或不存在的情况。尽管在接受沙利度胺治疗阿弗他病的HIV阳性患者中，使用沙利度胺与血栓形成之间关联的强度尚不清楚，但HIV治疗提供者应意识到所有接受沙利度胺治疗的患者都存在血栓形成的潜在风险。
